| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
1,430,000,000 |
| Market
Cap: |
106.75(B) |
| Last
Volume: |
6,978,222 |
Avg
Vol: |
8,439,653 |
| 52
Week Range: |
$48.64 - $74.55 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 297 |
| Guru Rank Value : 4.1 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
131,028 |
294,034 |
784,747 |
1,896,260 |
| Total Sell Value |
$9,081,880 |
$18,529,068 |
$44,400,077 |
$93,901,157 |
| Total People Sold |
8 |
9 |
11 |
13 |
| Total Sell Transactions |
13 |
22 |
38 |
73 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Capello Jeffrey D |
EVP & Chief Financial Officer |
• – – |
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,242 |
120,807 |
|
- |
|
| Dawkins Keith D |
Sr. VP, Global Chief Med. Off. |
• – – |
2012-02-16 |
4 |
D |
$5.97 |
$7,230 |
D/D |
(1,211) |
56,980 |
|
- |
|
| Dawkins Keith D |
Sr. VP, Global Chief Med. Off. |
• – – |
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,373 |
58,191 |
|
- |
|
| Pierce David A |
SVP and President, Endoscopy |
• – – |
2012-02-13 |
4 |
D |
$5.94 |
$3,427 |
D/D |
(577) |
3,089 |
|
- |
|
| Pierce David A |
SVP and President, Endoscopy |
• – – |
2012-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,605 |
3,666 |
|
- |
|
| Onuscheck John Michael |
SVP & President, EMEA |
• – – |
2012-02-13 |
4 |
D |
$5.94 |
$4,116 |
D/D |
(693) |
47,978 |
|
- |
|
| Onuscheck John Michael |
SVP & President, EMEA |
• – – |
2012-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,638 |
48,671 |
|
- |
|
| Kucheman William |
Chief Executive Officer |
• • – |
2012-02-12 |
4 |
D |
$5.93 |
$7,774 |
D/D |
(1,311) |
81,712 |
|
- |
|
| Kucheman William |
Chief Executive Officer |
• • – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,993 |
83,023 |
|
- |
|
| Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$6,991 |
D/D |
(1,179) |
64,410 |
|
- |
|
| Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,194 |
65,589 |
|
- |
|
| Neumann Lawrence R |
SVP and Pres, Emerging Markets |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$6,292 |
D/D |
(1,061) |
67,434 |
|
- |
|
| Neumann Lawrence R |
SVP and Pres, Emerging Markets |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,955 |
68,495 |
|
- |
|
| Pucel Kenneth |
EVP, Global Ops & Technology |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$10,490 |
D/D |
(1,769) |
93,747 |
|
- |
|
| Pucel Kenneth |
EVP, Global Ops & Technology |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,792 |
95,516 |
|
- |
|
| Onuscheck John Michael |
SVP & President, EMEA |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$10,022 |
D/D |
(1,690) |
47,033 |
|
- |
|
| Onuscheck John Michael |
SVP & President, EMEA |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,993 |
48,723 |
|
- |
|
| Nanavaty Maulik |
SVP & Pres, Neuromodulation |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$9,802 |
D/D |
(1,653) |
51,984 |
|
- |
|
| Nanavaty Maulik |
SVP & Pres, Neuromodulation |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,391 |
53,637 |
|
- |
|
| Pedersen John B. |
Pres, Uro & Womens Health |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$2,129 |
D/D |
(359) |
639 |
|
- |
|
| Pedersen John B. |
Pres, Uro & Womens Health |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
998 |
998 |
|
- |
|
| Phalen Michael P. |
EVP & President, MedSurg |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$6,974 |
D/D |
(1,176) |
46,054 |
|
- |
|
| Phalen Michael P. |
EVP & President, MedSurg |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,274 |
47,230 |
|
- |
|
| Fitzgerald Joseph Michael |
SVP & President, CRM |
• – – |
2012-02-12 |
4 |
D |
$5.93 |
$4,370 |
D/D |
(737) |
62,524 |
|
- |
|
| Fitzgerald Joseph Michael |
SVP & President, CRM |
• – – |
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,996 |
63,261 |
|
- |
|
1828 Records found
|
|
Page 23 of 74 |
|
|
0.10 (0.13%) 
